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A prospective analysis of mucosal 
microbiome-metabonome 
interactions in colorectal cancer 
using a combined MAS ͷHNMR and 
metataxonomic strategy
James Kinrossͷ, Reza Mirnezamiͷ, James Alexanderͺ, Richard Brownͻ, Alasdair Scottͷ, Dieter 
Galea͸, Kirill Veselkov͸, Rob Goldin͹, Ara Darziͷ, Jeremy Nicholson͸ & Julian R. Marchesiͺ,ͻ
Colon cancer induces a state of mucosal dysbiosis with associated niche speciic changes in the gut 
microbiota. However, the key metabolic functions of these bacteria remain unclear. We performed 
a prospective observational study in patients undergoing elective surgery for colon cancer without 
mechanical bowel preparation (n = ͷ;). Using ͷͼ S rRNA gene sequencing we demonstrated that 
microbiota ecology appears to be cancer stage-speciic and strongly associated with histological 
features of poor prognosis. Fusobacteria (p < Ͷ.ͶͶͽ) and ε- Proteobacteria (p < Ͷ.Ͷͷ) were enriched 
on tumour when compared to adjacent normal mucosal tissue, and fusobacteria and β-Proteobacteria 
levels increased with advancing cancer stage (p = Ͷ.Ͷͷͺ and Ͷ.ͶͶ͸ respecitvely). Metabonomic analysis 
using ͷH Magic Angle Spinning Nuclear Magnetic Resonsance  (MAS-NMR) spectroscopy, demonstrated 
increased abundance of taurine, isoglutamine, choline, lactate, phenylalanine and tyrosine and 
decreased levels of lipids and triglycerides in tumour relative to adjacent healthy tissue. Network 
analysis revealed that bacteria associated with poor prognostic features were not responsible for the 
modiication of the cancer mucosal metabonome. Thus the colon cancer mucosal microbiome evolves 
with cancer stage to meet the demands of cancer metabolism. Passenger microbiota may play a role in 
the maintenance of cancer mucosal metabolic homeostasis but these metabolic functions may not be 
stage speciic.
Sporadic colorectal cancer (CRC) is the third commonest cause of cancer-related death worldwide and its global 
incidence is increasing1. here is strong epidemiological evidence to suggest that diet (high in red meat and fat; 
low in iber) is a risk factor that may explain this trend2, but the interaction between the colon and its environ-
ment is complex and subject to personalized variation and dynamic xeno-metabolite interactions. Nevertheless, 
data now exist to support the hypothesis that an important environmental driver of CRC risk is the colonic micro-
biota and its associated metabonome3, 4. For example, it has been demonstrated that the metabolic function of the 
colonic microbiota directly inluences cancer risk through its modulation of dietary iber, an increase of which 
leads to profound changes in colonic ecological co-occurrence networks with resulting upregulation of butyrate 
metabolism and a reduction in the metabolism of secondary bile acids3.
Several competing theories regarding the microbial regulation of CRC have now emerged to explain the func-
tion and importance of the CRC-associated metagenome (the catalogue of microbial genes that reside within 
the gut). he keystone-pathogen hypothesis5 and the Alpha-Bug hypothesis state that certain low abundance 
microbiome members may possess unique virulence or amensalistic traits, or produce carcinogens, which are 
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not only pro-oncogenic, but also promote a mucosal immune response and colonic epithelial cell changes that 
initiate colorectal carcinogenesis6. Tjalsma and colleagues proposed the alternative ‘driver passenger’ model 
for CRC, whereby a ‘irst hit’ by indigenous intestinal ‘driver’ bacteria causes epithelial DNA damage, which in 
turn contributes to the initiation of CRC7. he consequent developing tumor induces intestinal niche alterations 
that favour the proliferation of opportunistic bacteria (termed bacterial ‘passengers’). Pathobionts are commen-
sal organisms that can cause disease when speciic genetic or environmental conditions are altered in the host. 
Colonic pathobionts may be able to inluence host pathogenesis through a large number of chemical and molec-
ular signaling pathways. Whether these pathobionts create a speciic mucosal metabolic microenvironment that 
potentiates tumour growth remains unclear.
Important weaknesses of many existing studies examining the colonic microbiota in cancer aetiology are the 
employment of heterogeneous sampling approaches, the limited oncological phenotyping data presented and 
the variable use of mechanical bowel preparation8–16. his heterogeneity is critical as such variation is likely to 
inluence the ecological characteristics of the microbiota: for example recent data from patients undergoing lower 
gastrointestinal tract endoscopy have identiied short-term changes in the colonic microbiome caused by use of 
mechanical bowel preparation17, 18.
he metabolism of colon cancer is complex, and although fundamental changes in faecal amino acid and 
microbial co-metabolites (such as choline) have been demonstrated, mucosal microbiome-host metabolic inter-
actions have yet to be fully deined19–21. he primary aim of this study, therefore, was to describe the variation 
in local colonic dysbiosis between tumor and normal mucosa in a homogeneous group of CRC patients, in the 
absence of mechanical bowel preparation. Further, we aimed to determine the local ecology of the cancer micro-
biome in the context of cancer phenotype and stage, as deined by the ‘passenger-driver hypothesis’. he second-
ary aim was to describe mucosal microbiome-metabonome interactions that modulate metabolism at the level of 
the CRC mucosa20, 21.
Results
Patient Demographics. Demographic and clinicopathological data for the 18 patients included in the study 
are summarized in Table 1. here were no intraoperative complications and all patients made a routine recovery. 
he majority of cases were stage T3 and T4 tumours. hree patients had large tubulovillous adenomas with low 
grade dysplasia, which were resected due to concerning features suggestive of cancer on pre-operative imaging. 
A single T1 lesion (pT1N1, Dukes C1) and a T2 lesion were also analysed (pT2N0, Dukes B). Seven of 18 patients 
had nodal micrometastases (N1/N2). No patients had evidence of distant metastatic disease at the time of surgery. 
he majority of lesions were adenocarcinomas (15 out of 18) of which ive were of mucinous type. Five patients 
Age (Median) 76 (55–85)
Sex (M:F) 10:8
BMI (Mean) 26.6 (21–39)
Anatomical location
 Ascending colon 16
 Descending colon 2
T stage
 T0 (TVAs) 3
 T1 1
 T2 1
 T3 5
 T4 8
N stage
 N0 11
 N1 4
 N2 3
Histological subtype
 Adenocarcinoma 15
 Dysplasia 3
Diferentiation
 Well 1
 Moderate 11
 Poor 6
Perineural invasion 1
Lymphovascular invasion (LVI) 6
Extramural vascular invasion (EMVI) 5
KRAS mutants 2
Table 1. Patient demographic and pathological data. BMI: Body Mass Index; TVA: Tubulovillous adenoma; 
KRAS: Kirsten rat sarcoma viral oncogene homolog.
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had extramural vascular invasion (EMVI), which is a histological feature of poor prognosis, and two of these were 
found to express the KRAS mutation.
Metataxonomy data. here were no signiicant diferences in Tau or Shannon indices of diversity when 
comparing samples on tumour, 5 cm of tumour and 10 cm of tumour (Fig. 1a), although there was a trend 
observed towards increased diversity of tumour, which was greatest at 10 cm. his inding was conirmed by 
non-metric multidimensional scaling of Operational Taxanomic Unit (OTU) data (Fig. 1c) which showed no 
signiicant class separation according to tumour, 5 cm and 10 cm sites. However, as previously described in other 
studies, the 16 s rRNA data demonstrated that Fusobacterium was over-represented in cancer biopsies. 8/18 (44%) 
patients had Fusobacterium both on and of tumour. 6/18 (33%) patients did not have Fusobacterium on the 
tumour, and of these only one patient had Fusobacterium at an of cancer site (at 5 cm). 4/18 patients (22%) only 
had Fusobacterium on tumour. In keeping with these inidngs, Fusobacterium nucleatum-speciic qPCR analysis 
conirmed over-representation of this species on tumour compared to 10 cm of tumour (p < 0.05) (Fig. 1b).
Dendrogram analysis (Fig. 2A) demonstrated three dominant bacterial clusters: 1) Bacteroides, Lachnospiracea 
intertie sedis, Blautia, Fusobacterium and Streptococcus; 2) Bacteroides, Lachnospiracea intertie sedis, Clostridium 
sensu strictu, Sutterella, Salmonella, and Escherichia/Shigella; 3) Lachnospiracea intertie sedis Streptococcus, 
Prevotella and Paraprevotella. Using multivariate statistical modelling, these clusters could be categorized by T 
stage (p = 0.04), histological subtype (p = 0.05) and tumour diferentiation (p = 0.011) (Supplementary data, 
Table 1). Univariate statistical analysis demonstrated Cluster 1 and 2 contained patients with dysplastic lesions 
and less advanced cancers, and class 2 only contained patients with moderately diferentiated tumours. Cluster 
3 (8 patients) was made up of patients with T4 adenocarcinomas with poor tumour diferentiation, and a trend 
towards nodal metastases.
On and of tumour samples from individual patients also clustered together (Fig. 2B). 8 out of 18 patients 
had on tumour, 5 cm and 10 cm samples that clustered together. hese patients tended to have histological fea-
tures associated with a better oncological prognosis. he absence of nodal metastases (p = 0.017) and moderate 
Figure 1. (a) Boxplots of the ecological Indices for the tumour (CT, n = 18), 5 cm of the tumour (ive, n = 18) 
and 10 cm of the tumour (ten, n = 18). Each boxplot was calculated from the individual Tau index (A), Shannon 
index (B), Normalized Tau (values normalized to the on tumour (CT) value for each individual) (C) and 
Normalized Shannon (values normalized to the on tumour (CT) value for each individual) (D). No statistical 
diferences were observed between the values. (b). Box plot of Fusobacterium nucleatum 16 S qPCR data, 
demonstrating over-representation of Fusobacterium nucleatum on cancer, when compared to mucosa biopsied 
at 10cms (p < 0.05). (c). PCA plot of non-metric multi-dimensional scaling of OTU data from 18 patients in this 
study, conirming that there was no multivariate statistically signiicant ecological variance between on tumour, 
5 cm of tumour and 10 cm of tumour sampling points.
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tumour diferentiation (p = 0.038) were statistically signiicant for factors for diferentiating between these two 
cohorts, with non-signiicant trends also noted for T stage, histological subtype and Lymphovascular invasion 
(LVI) (Supplementary data Table 2). Collectively, these data suggest that individual patient variation has a greater 
inluence on CRC microbiome dysbiosis than colonic geographical sampling site relative to the tumour. Perhaps 
more critically, the mucosal tumour phenotype is associated with three distinct microbial structures, and eco-
logical heterogeneity between on and of tumour biopsy sites from the same patient is associated with poorer 
prognostic features on histological examination.
hese indings were further investigated using a univariate analysis of the entire 16 S rRNA data set from 
tumour, 5 cm and 10 cm sites. (Table 2). Histologically poorly diferentiated tumors had higher relative abundance 
of Fusobacterium (P < 0.03). hree classes of bacteria belonging to the Firmicutes (F. streptococcus spp. ( < 0.03), F. 
Solobacterium spp. (P < 0.01). and Clostridium XI spp. (P < 0.04)) were also over represented in poorly diferen-
tiated tumours while F. subdoligranulum spp. was under represented (P < 0.01). When a univariate analysis was 
applied to other histological biomarkers of poor prognosis, such as extra-mural vascular invasion (EMVI), LVI 
and KRAS mutation status, there were no statistically signiicant associations with abundance of Fusobacterium 
(data not shown). However, increased Bacteroidetes, Bacteroides spp. abundance was associated with EMVI 
(p < 0.03) and Firmicutes, Roseburia spp. was associated with the presence of LVI (p < 0.02). Proteobacteria, 
Aggregatibacter spp. (P < 0.01) was associated with KRAS mutation (P < 0.01), although this inding requires 
caution as the patient numbers expressing KRAS mutation were small.
A multivariate analysis of the entire data set was then performed to determine if the data had clinical util-
ity. Principle component analysis (PCA) identiied three outliers (two from a patient with tubular villous ade-
noma and one from a patient with a T4 tumour) and these samples were removed, leaving 51 for further analysis 
(Supplementary data, Fig. 1). Supervised analysis was performed using Partial Least Squares discriminant anal-
ysis (PLS-DA) of mucosal ecology and models were built for all histological features of prognostic signiicance 
Figure 2. (A) Heatmap and (B) Clustering dendrogram (Bray-Curtis and Ward linkage) for genus-level OTU 
data. Figure A. demonstrates that three clusters of mucosal bacteria predmoninate and that on and of cancer 
samples appear to cluster together. In (B) the grey boxes highlight samples taken from tumour, 5 cm of tumour 
and 10 cm of tumour from the same individuals which cluster together. his shows that 8 out of 18 patients 
demonstrated signiicant homogeneity in mucosal bacteria on cancer and at 5 and 10 cms. his clustering efect 
is greater than any clustering associated with sampling location, suggesting that individual variation is a greater 
inluence on CRC microbiome dysbiosis than colonic geographical sampling site relative to the tumour.
EMVI P KRAS p LVI p Diferentiation p
Bacteroidetes 
Bacteroides ↑
0.03
Proteobacteria 
Aggregatibacter ↑
0.01
Firmicutes 
Roseburia ↓
0.02
Firmicutes 
Streptococcus ↑
0.029
Firmicutes 
Solobacterium ↑
0.01
Firmicutes 
Clostridium XI ↑
0.039
Firmicutes 
Subdoligranulum ↓
0.01
Fusobacteria 
Fusobacterium ↑
0.033
Table 2. Summary data of bacteria statistically over- or under-expressed in tumour samples and their statistical 
association with established histological biomarkers of poor prognosis. (EMVI = Extra mural vascular invasion, 
LVI = Lymphovascular invasion).
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(Fig. 3). his analysis demonstrated that discrete clustering of samples was possible for all features analysed 
(Fig. 3a to h). Leave one sample out cross-validation revealed that the diagnostic accuracy was high for each 
feature (Supplementary data, Table 3). Reciever operating curves were then created (Supplementary data, Fig. 2) 
for EMVI (Area under curve (AUC) = 0.95), LVI (AUC 0.97), tumour diferentiation (AUC 0.95) and KRAS 
mutation status (AUC 1.0). hese data suggest that tumours of a poor prognostic phenotype maintain conserved 
components of the microbiome that correlate with the degree of tumour invasiveness and histological biomarkers 
of relevance to clinical outcomes.
ͷNMR and metabolic network analysis. MAS-NMR analysis of tumour and healthy mucosa was per-
formed as an untargeted analysis of mucosal metabolism during cancer progression. he summary data are 
reported in Fig. 4 and in Table 3.
As demonstrated in a previous study21, colonic mucosal metabolites are highly diagnostic of cancer (Fig. 4a 
and b). In contrast to the microbiome data presented here, clear metabolic separation was demonstrated between 
tumour and of tumour mucosal samples. Lipids and triglycerides were statistically important metabolic descrip-
tors (Fig. 4c) for deining this variation and speciically they were positively correlated with on tumour metab-
olism. Molecules that showed signiicant statistical correlation with tumour or normal mucosal tissue status 
Figure 3. (a–h) Partial Least Squares-discriminant analysis scores plots of OTU data for important 
prognostic features identiied by histopathological and molecular analysis. LVI = Lymphovascular invasion. 
EMVI = Extramural vascular invasion. PNVI = Perineural vascular invasion.
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Figure 4. High Resolution – Magic Angle Spinning (HR-MAS) Nuclear Magnetic Resonance (NMR) analysis 
of mucosal metabolism using orthogonal partial least squares discriminant analysis. (a) Cross validated scores 
plot using Maximum Margin Criteria, and a leave one patient out validation. (b) he corresponding ROC curve 
demonstrating the diagnostic accuracy of the model (AUC 0.96). (c) Pseudo-loadings ANOVA plot of the MMC 
cross validated model, demonstrating co-variance of metabolites between on and of cancer sampling points. 
he colour code provides a visual description of FDR p values for each signal. Peaks point in the direction of 
the tissue state with which they are positively associated (up or down) and signals red in colour have greater 
statistical signiicance.
Chemical structure ppm
Expression 
in cancer p
1 Acetate -CH3 1.92(s) ↓ 0.4
2 Alanine -CH3 1.47 (d) ↑ 0.0002
3 Creatine -CH3, -CH2 3.02 (s), 3.93(s) → 0.89
4 Formate -CH2 8.45 (s) ↑ 0.002
5 Glycerophosphorylcholine N(CH3)3 3.22 ↑ 0.016
6 Glycine CH2 3.56 ↑ 0.00005
7 Iso-butyrate -CH3 1.0 (d) ↓ 0.41
8 Isoglutamine β-CH2 2.34 ↑ 0.001
9 Lactate -CH3, -CH- 1.33 (d), 4.15 (q) ↑
7.69 × 10–
9
10 Leucine β-CH2 γ -CH 1.72 → 0.19
11 Lipid/Triglyceride C = C-CH2 2.02 ↓ 0.02
12 Lipid/Triglyceride 1(CH2)n 1.29 ↓ 0.002
13 Lipid/Triglyceride -CH3 0.9 ↓ 0.001
14 Phosphocholine N(CH3)3, O-CH2 3.22(s), 4.19(t) ↑ 0.007
15 Scylloinositol -O-H 3.34 ↑ 0.67
16 Taurine -CH2-NH, CH2SO3 3.26, 3.42 ↑
2.01 × 10–
9
17 Valine -CH3 1.02 → 0.49
Table 3. Summary of signiicant metabolites, their observed trends in terms of abundance (↑, ↓, ↔) with 
corresponding p-values, their chemical formulae and chemical shit assignments.
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are shown in Table 3. hese molecules were then regressed against the OTU data set to determine mucosal 
microbiome-metabonome functional associations that may be important in the maintenance of the cancer 
mucosal metabolic environment (Fig. 5). his analysis demonstrated that the network difers between on tumour 
and of tumour (normal healthy mucosa) sites. Only Shewanella spp. demonstrated commonality between these 
two tissue classes. OTUs associated with poor histological prognostic biomarkers did not demonstrate any statis-
tical correlation, with the exception of Proteobacteria. Spp., which appeared to be linked to lipid, choline, taurine, 
acetate, and creatine metabolite expression. he tumour network did demonstrate greater network connectivity 
than the of tumour network, suggesting that the bacteria residing ‘on tumour’ have a greater catalogue of meta-
bolic functions.
A secondary analysis was then performed to determine if these associations were consistent according to 
tumour stage. his analysis was limited by the small sample size for each stage, so no statistically signiicant 
interpretation was achieved (Supplementary data, Fig. 3). Correlations for Stage 0/1, 3 and 4 based on a p-value 
threshold of 0.05 demonstrated that only Comamonadaceae acidovrax spp. was consistently correlated with lipid 
metabolism across all stages of cancers. his Gram negative, aerobic genus is enriched in the mucosal biopsies of 
patients with inlammatory bowel disease, but its role in colon cancer is not established22.
Discussion
Several species of pathobionts have now been implicated in the aetiology of colon cancer23, 24. In particular, the 
oral Gram negative bacterium Fusobacterium nucleatum has been strongly associated with adenomas of the 
colon and rectum12, 15, 16, 25. Moreover, there is evidence that the presence of Fusobacterium may be of prognostic 
importance as it is associated with CIMP positivity, TP53 wild-type, hMLH1 methylation positivity, Microsatellite 
Instability (MSI), and CHD7/8 mutation positivity26. However, many of the conclusions of such studies have 
been limited by methodological issues such as heterogeneity in sampling protocols and relatively small numbers 
of patients. Perhaps most importantly, there is oten a lack of adequate clinical phenotyping data, and a false 
assumption that all colon cancers are homogeneous. he current study has therefore attempted to address some 
of the major confounders in translational microbiome research, including our uniform sampling of tumours 
without the use of bowel preparation. In preference to the faecal microbiota, we have targeted the CRC mucosal 
microbiome to provide a focussed analysis of histological prognostic factors that inform current clinical practice 
as part of a prospective clinical study.
Under these conditions, we have replicated key indings from other studies, including that the bacterium F. 
nucelatum is over represented on colorectal tumours. However, a major conclusion of our work is that mucosal 
populations are dynamic with advancing cancer stage, and that the CRC microbiome story is therefore more 
complex than the over representation of a small number of organisms. here was no signiicant variation in 
the microbiome ecology of normal associated mucosa over relatively short distances from the primary tumour 
site. his inding is in keeping with recent data from a larger cohort of patients27 and suggests that dysbiosis in 
colorectal cancer may pervade the whole colon. Inter-individual variation is marked and based on this analysis, 
true ‘healthy’ mucosa should be biopsied from consistent geographically discrete regions from non CRC-bearing 
individuals to provide a more representative ‘control’ sample of normal colonic ecology.
he data pesented here have also demonstrated more evidence in concordance with the colorectal cancer 
driver passenger theory7. Cancers of a poor prognostic phenotype were more likely to have over-representation 
of Lachnospiracea intertie sedis, Streptococcus, Prevotella and paraprevotella, (Table 2, Fig. 2). Individuals who 
demonstrated ecological similiarity between on and of cancer sites were more likely to have earlier cancers or 
tumours with better prognostic features.
Figure 5. Metabolic network map of mucosal metabolites statistically over and under-represented in colon 
cancer and normal associated mucosa (NAM) as detected by 1H NMR-MAS regressed against the 16s rDNA 
OTU data. he spp. in green are microbiota over-represented in the NAM and those in red are over-represented 
in cancer. Shewanella spp. was the only bacteria class represented in both models.
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Despite the dominance of inter-individual variation of microbiomes, using multivariate statistical models it 
was possible to deine clear associations between the 16 s rRNA gene OTU data and tumour stage (T and N stage) 
(Fig. 3). Moreover, it was possible to deine associations with established histopathological biomarkers of poor 
prognosis. Univariate interpretation of the data sets only demonstrated a small number of statistically meaningful 
associations with bacterial classes, with over-representation of Bacteroides spp., Aggregatibacter spp., Streptoccocus 
spp., Clostridium XI, Solobacterium spp. and F. nucleatum spp. associated with poor prognostic features. hese 
associations do not imply a causative link, but in the context of the cancer stage data, they suggest that the advanc-
ing CRC microbiome contains over-represented ‘passenger’ elements (described previously) which may have 
clinical relevance and utility.
he structure of the CRC microbiome is increasingly well-deined, but its function in this context is less well 
understood. It is highly likely that the combined metabolic function of the mucosal network of bacteria plays a 
critical role in deining its impact on cancer initiation and progression3. Indeed a recent study of human fecal 
samples demonstrated strong microbe-metabolite correlations in CRC patients28. However, this metabolic func-
tion requires greater elucidation. We have previously demonstrated that the mucosal metabonome has a high 
diagnostic sensitivity and speciicity between ‘on’ and ‘of ’ cancer samples20, 21, which is deined by disruption 
to lipid metabolism. he diagnostic accuracy of MAS-NMR spectroscopy for CRC was replicated in the current 
analysis (Fig. 4), and subtle metabolic changes driven by microbial co-metabolism are integral to the model’s 
strength. We were able to correlate this metabolic data with 16 s rRNA gene sequencing to assess if the microbiota 
inluences metabolic pathways on and of cancer. We have shown that the metabonome-microbiome metabolic 
network varies considerably between on and of tumour sites. his is only a statistical association, but it suggests 
that the mucosal microbiome has an important part to play in the maintenance of the cancer metabolic environ-
ment. Interestingly, the microbiota associated with histological features of poor prognosis were not associated 
with the metabolites which featured in the network analysis. his inding may imply that such classes of bacteria 
exert pathological inluence via other molecular pathways, or that these are ‘passenger’ microbiota that reside on 
the mucosa of colorectal cancers and have a metabolic function that does not relate to tumour progression. he 
proteobacteria OTUs represented a statistically signiicant node on the network map, correlating with lipid, phos-
phocholine and taurine metabolism, which are strong metabolic biomarkers for cancer. Only the Shewanella spp 
demonstrated commonality between on and of tumour positions. hese are marine bacteria, which have been 
shown to possess enzyme functions reminiscent of eukaryotic pepsin homologues29.
Abnormal choline metabolism is emerging as a metabolic hallmark associated with oncogenesis and tumour 
progression. We have previously identiied choline as a biomarker of colon cancer risk in susceptible individuals 
associated with altered microbiome metabolism3. Microbiome modulated metabolism of choline is also closely 
associated with cardiovascular disease30. Phosphocholine is both a precursor and a breakdown product of phos-
phatidylcholine, which, together with other phospholipids such as phosphatidylethanolamine and neutral lipids, 
forms the characteristic bilayer structure of cellular membranes and regulates membrane integrity. It is not clear 
whether altered choline metabolism, and secondary choline metabolites, inluence microbiome abundance in 
CRC, or vice versa. he small number of patients with early cancer in this study means that subgroup analysis 
was not possible. Nevertheless, this work provides further evidence that microbiome modulation of the choline 
metabolic pathway is an important inluence on the cancer metabolic niche.
here are some obvious limitations with this work. Firstly, the sample size is small, particularly for patients 
with speciic molecular features such as KRAS mutation. 16 S rRNA gene analysis does not permit strain level 
assignment of bacteria and as a result, it is not possible to investigate the speciic metabolic functions of target 
strains. In this study we applied a non-targeted 1H HR-MAS NMR approach to the metabolic analysis, so we 
have not been able to report on certain established metabolites known to have important pro or anti-neoplastic 
efects (e.g. bile acids and short chain fatty acids). We also acknowledge that linking metabolic data such as these 
to taxanomic data is statistically challenging using clinical sample sets. But despite these limitations, the present 
work has identiied novel bacterial classes associated with adverse histopathological features in CRC and it has 
provided more data to support the ‘driver - passenger model’ as an important mechanism in the aetiology and 
progression of colon cancer. Moreover, ours is the irst study to use 1 H MAS-NMR data linked to a robustly 
sampled 16 S rRNA data set from well phenotyped patients and it provides a basis for the metabolic function of 
commensal bacteria at the level of the mucosa in cancer.
In conclusion, the cancer mucosal microbiome is individualized, and evolves with cancer stage to meet the 
demands of cancer metabolism. In addition to normal associated mucosa from CRC patients, which may not be 
representative of a healthy gut microbiome, future studies should also use control samples from non CRC-bearing 
individuals. It remains to be proven that ‘driver’ species of the mucosal microbiota modulate cancer initiation, but 
this study suggests that ‘passenger’ bacteria in the evolving CRC microbiota may play a role in the maintenance of 
tumoral metabolic homeostasis and could serve as useful clinical biomarkers.
Methods
Patient recruitment and sampling. Between November 2011 and September 2012 tissue specimens 
and related clinico-pathological data were collected with informed written consent from 18 patients undergoing 
planned surgical resection for right sided colorectal cancer, at a single cancer referral center (St Mary’s Hospital 
(London, UK)). Inclusion criteria were: patients with histologically conirmed invasive malignancy or high-grade 
dysplasia of the colon, having either open or laparoscopic surgery without the use of bowel preparation. Exclusion 
criteria were: patients undergoing emergency surgery, patients treated with neoadjuvant chemotherapy and/or 
radiotherapy, patients who had been on antibiotics or probiotic therapies within the previous six weeks and 
patients with rectal cancers (deined here as tumours lying within 15 cm of the anal verge). Patients with a history 
of Familial Adenomatous Polyposis (FAP) were also excluded as were patients with inlammatory bowel dis-
ease or those who had undergone previous colorectal surgery. At induction, patients had an intravenous dose of 
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cefuroxime and metronidazole as per standard local hospital protocol. At surgery, fresh tissue samples were har-
vested from the tumour centre and at 5 cm and 10 cm away from the tumour. Tissue harvesting was performed in 
the pathology department by a single gastrointestinal histopathologist (RDG) and acquired samples were imme-
diately transferred to a freezer at −80 °C.
DNA Extraction and proiling of ͷͼ S rRNA genes. Total DNA was extracted from biopsies using 
MO BIO’s powersoil DNA isolation kit. The V1-V3 regions of the 16 S rRNA genes were amplified (28 F 
5’-GAGTTTGATCNTGGCTCAG and 519 R 5’-GTNTTACNGCGGCKGCTG) and sequenced on a Roche 454 
platform by Research and Testing Laboratory (Austin, Texas, USA). he sequences were processed using Mothur 
to remove low quality sequences and chimeras31, 32. All samples were normalized to the lowest number of reads 
using the subsample command in Mothur and alpha and beta diversity indices were calculated. All other statisti-
cal analysis and multi-variate analysis of the 16 S rRNA proiles was performed in R.
qPCR to enumerate Fusobacterium nucleatum in extracted DNA. Biopsy colonisation by 
Fusobacterium nucleatum was assessed by qPCR of the 16 S rRNA genes in the DNA extracts normalised to 
sample total generic pan bacterial 16 S rRNA copies, expressed as the diference in respective qPCR threshold 
emergence cycle time (Ct) of generic and speciic Fusobacterium nucleatum. Ct is inversely proportional to copy 
number so the smaller the diference the greater the relative quantity of speciic Fusobacterium nucleatum DNA 
and hence the degree of biopsy colonisation.
Fu s ob a c te r ium  nu c l e atum  pr i m e r s  w e re  5 2 7  F  G G AT T TAT T G G G C G TA A AG C  a n d 
689 R GGCATTCCTACAAATATCTACGAA16.  Pan bacterial  16 S qPCR primers were 343 F 
TCCTACGGGAGGCAGCAGT and 809 R GGACTACCAGGGTATCTAATCCTGTT. he qPCR used Maxima 
Mastermix SYBR green (hermo-Fisher) with lots pre-screened for minimal endogenous bacterial 16 S DNA 
background suicient to permit 30 PCR cycles. Cycling details: 95 °C 10 minutes, then 30 cycles of 95 °C 15 sec-
onds and 60 °C 60 seconds. Melt curve analysis was used to determine amplicon idelity.
MAS NMR sample preparation. Tissue samples were kept on ice at all times during the preparation pro-
cess to minimize metabolite degradation. Where tissue volume permitted, 2 replicates were prepared for High 
Resolution – Magic Angle Spinning (HR-MAS) Nuclear Magnetic Resonance (NMR) analysis from each orig-
inal tissue sample, to compensate for anticipated tissue heterogeneity. Sampling was performed using a dispos-
able punch biopsy device, ater which 12–15 mg of tissue was packed into disposable 30 µL Telon NMR inserts. 
Deuterated water (D2O) was next added to the insert to complete required volume and homogenize insert con-
tents. Inserts were introduced into zirconium oxide rotors for analysis. he spectroscopic proiling approach 
employed in the present study has been previously described by our group21. In summary, 1-dimensional 1H 
Carr-Purcell-Meiboom-Gill (CPMG) spectra were acquired using a Bruker Avance III 400-MHz spectrometer 
equipped with magic angle spinning probe (Bruker BioSpin GmbH, Rheinstetten, Germany). A water suppres-
sion pulse was applied during experimentation to minimize the water signal. Acquired spectra were processed 
using Bruker sotware packages (TopSpin v.2.2 and Amix v.3.9.9), and the methyl signal of alanine was used for 
spectral calibration (1.47 ppm). Spectral metabolite identiication and chemical assignment were performed on 
the basis of the literature21, 33, 34 and using statistical total correlation spectroscopy approaches for data-driven 
structural assignment35, 36.
Statistical analysis. Phased and baseline corrected CPMG spectra were converted into statistical matrices 
using in-house tools developed in MATLAB (v.7.12.0.635; he MathWorks, Inc., Natick, MA, USA). he matrix 
contained information from the region −1 to 10 ppm, and the resolution used was 0.00055 ppm21. Spectral peaks 
corresponding to water (4.50–5.19 ppm), ethanol (1.10–1.20, 3.60–3.90 ppm), and polyethylene glycol (3.70–3.75 
ppm) signals were excluded from the analysis because these chemical regions do not provide biologically relevant 
information. Spectral pre-processing involved probabilistic quotient normalization and unit variance scaling. 
Processed data were subjected to both univariate and multivariate analyses. For univariate analysis, we used anal-
ysis of variance to identify the statistical signiicance (reported as P values) of the discriminatory capacity of indi-
vidual metabolic features. Ecological analysis was performed using the Tau (for similarity) and Shannon indices 
(for community diversity). Data were normalized to the on tumour value for each individual. Community cluster-
ing was assessed using the Bray-Curtis distances of the genus-level OTU reads, using the Ward linkage algorithm.
For multivariate analysis, we used unsupervised principal component analysis (PCA) and supervised orthog-
onal partial least squares–discriminant analysis (OPLS-DA) using in-house developed scripts operating in a 
MATLAB environment. For each generated OPLS model cross-validated Q2 values were obtained before model 
robustness was further assessed by calculating the area under the curve (AUC) from corresponding receiver oper-
ating characteristic (ROC) curves37. Where OPLS score scatter plots revealed separation between classes, loadings 
plots were generated and assessed to identify the metabolites most responsible for discrimination. Additionally, 
correlation-driven network analysis was used to construct dependencies between metabolites in tumor and 
healthy mucosal tissues. he correlation coeicients between metabolites were calculated via non-parametric 
Spearman metrics. he spring embedding algorithm was used to calculate the optimum layouts of metabolite 
correlation networks38.
Ethics approval and consent to participate:. his study was granted full ethical approval by the insti-
tutionalreview board at Imperial College Healthcare NHS Trust (REC reference number 07/H0712/112). All 
experiments were carried out in accordance with relevant guidelines and regulations.
Availability of data and material:. he 16 S rRNA gene sequences supporting the results of this article is 
available at the EBI’s ENA short read archive under number PRJEB13249.
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